Monthly Archives: January 2012

Today Celgene announced the acquisition of Avila Therapeutics for $350M upfront and up to $575M in future milestones.  Congratulations to the Avila team!  For those of us involved in the story, we certainly think Celgene’s got itself a great deal.

Today’s headlines were replete with the customary quarterly whinging about biotech funding. Several pieces emphasize the doom and gloom in the startup biotech landscape, and include quotes from respected venture investors lamenting the end of early stage and the broken

Corporate venture capital’s role in the new biotech ecosystem couldn’t be understated today.  They are a major syndicate partner for those of us in the early stage arena, and we couldn’t power up our startups without them. I’ve written on

It’s certainly not Breaking News that M&A deals are an important source of liquidity in biotech VC today.  But last year did mark an important milestone for biotech over the past few years: in 2011, the capital returned to investors

Flying home from JPM 2012 and thought I’d share a few reflections from our early stage venture perspective on what we heard (or didn’t) around the year’s kickoff biotech event. While most of the attendees were focused on Inhibitex and

Happy New Year! Its another January and we’re taking stock of last year and pondering the one before us. Reflecting on the Life Science landscape, there are a number of good reasons to be optimistic about where things are today: